Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Clinical Evaluation of an Investigational Blood Creatinine Point-of-Care Test Device

This study has been completed.
Nova Biomedical Corporation
Information provided by:
Memorial Sloan Kettering Cancer Center Identifier:
First received: January 22, 2008
Last updated: June 3, 2010
Last verified: June 2010
This study is being done to see if the Nova Creatinine Meter can give a correct measure of creatinine (a blood test used to measure kidney function) when the blood is taken from a capillary (smallest type of blood vessels). The Nova Creatinine Meter is a hand held device that can be used in a clinic to measure creatinine in about 50 seconds. Current laboratory creatinine testing can take up to an hour. Since chemotherapy patients need to have their creatinine measured prior to treatment, this meter could make testing easier and faster.

Condition Intervention
Other: hand-held POC creatinine analyzer-blood test

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Clinical Evaluation of an Investigational Blood Creatinine Point-of-Care Test Device

Resource links provided by NLM:

Further study details as provided by Memorial Sloan Kettering Cancer Center:

Primary Outcome Measures:
  • The primary outcomes would be, reduced wait time and increased patient satisfaction. [ Time Frame: conclusion of the study ]

Secondary Outcome Measures:
  • reduced blood loss [ Time Frame: conclusion of the study ]

Biospecimen Retention:   Samples Without DNA

Enrollment: 99
Study Start Date: August 2007
Study Completion Date: May 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Patients having a creatinine drawn
Other: hand-held POC creatinine analyzer-blood test
This study will require the collection of a finger-puncture capillary blood specimen in addition to one green stoppered heparin containing collection tube. This is taken pre-therapy. The capillary whole blood specimen will be used to perform a creatinine determination on the "investigational" hand-held creatinine analyzer using special test strips for the analysis.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
MSKCC patients

Inclusion Criteria:

  • Written Informed Consent
  • Must have a creatinine > or = to than 3.5 mg/dl

Exclusion Criteria:

  • Patients who are less than 18 years of age
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00607529

United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Nova Biomedical Corporation
Principal Investigator: Martin Fleisher, PhD Memorial Sloan Kettering Cancer Center
  More Information

Additional Information:
Responsible Party: Martin Fleisher, PhD, Memorial Sloan-Kettering Cancer Center Identifier: NCT00607529     History of Changes
Other Study ID Numbers: 07-023
Study First Received: January 22, 2008
Last Updated: June 3, 2010

Keywords provided by Memorial Sloan Kettering Cancer Center:
Multiple Diseases processed this record on April 28, 2017